Cardinal Health (CAH) is drawing new investor attention in mid 2026 as specialty pharmaceuticals, including oncology therapies, GLP-1 products, and branded medicines, become a larger focus alongside chronic care acquisitions.

At a share price of $228.72, Cardinal Health has posted an 11.18% year to date share price return. Its 44.92% 1 year total shareholder return and very large 5 year total shareholder return point to momentum that has carried through shorter term swings.

If you are watching how healthcare distributors are repositioning around specialty drugs, it can also be useful to scan a wider set of healthcare AI opportunities using the 39 healthcare AI stocks

Cardinal Health’s recent surge and growing focus on specialty services have some investors arguing the stock is still priced for caution. Others see a clear discount to fair value. Which side do the current valuation markers support?

Most Popular Narrative: 6.7% Undervalued

Cardinal Health’s most followed valuation narrative pegs fair value at $245.27, slightly above the recent $228.72 close, framing the stock as modestly discounted.

The analysts have a consensus price target of $245.27 for Cardinal Health based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $275.0, and the most bearish reporting a price target of just $215.0.

Want to see what sits behind that fair value gap? The narrative emphasizes revenue trends, margin dynamics and the valuation multiple applied to future profits. Curious how those elements combine into one valuation story?

Result: Fair Value of $245.27 (UNDERVALUED)

However, Cardinal Health still faces execution and policy risks, including contract expirations and reimbursement or tariff changes that could challenge the current undervalued narrative.

Another View: Cardinal Health Through the P/E Lens

Our DCF view suggests Cardinal Health is undervalued, but the simple earnings multiple tells a different story. At a P/E of 34.4x versus a peer average of 27.7x, a US Healthcare industry average of 25.5x and a fair ratio of 29.1x, the stock looks expensive. This raises the question of whether investors are paying up for quality or taking on valuation risk.

Next Steps

Seeing mixed signals on Cardinal Health's valuation and growth potential? Use the full picture of risks and rewards to pressure test your own thesis with the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Cardinal Health?

If Cardinal Health has sharpened your focus on quality, do not stop here. Broaden your watchlist with other ideas before the next opportunity moves out of reach.

• Stretch your opportunity set with carefully screened small caps that still meet strict quality checks using the 20 elite penny stocks with strong financials.
• Zero in on potential value opportunities where strong fundamentals come first by running the 49 high quality undervalued stocks.
• Prioritize resilience and capital preservation by scanning companies flagged in the 81 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.